secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001558370-24-007196
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study
--------------------------------------------------------------------------------

- Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.
- Net loss $17.4M for Q1 2024 vs $12.2M in Q1 2023; R&D expense $17.0M vs $10.2M.
- Fully enrolled Phase 1b FURTHER trial for firmonertinib in NSCLC EGFR PACC mutations; proof-of-concept data expected in 2024.
- Initiated Phase 1b combo study of firmonertinib and ICP-189 (SHP2 inhibitor) for EGFR classical mutation NSCLC.
- Appointed Kristine Peterson to Board; presented preclinical AACR data showing broad activity across uncommon EGFR mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/0001558370-24-007196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/avbp-20240508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer